OpenAI acquires Orchestra Bio to advance AI drug development

DIGITIMESOctober 22, 2026en

OpenAI has acquired biotech startup Orchestra Bio and will integrate its team and technology into its life sciences research platform, Rosalind, expanding AI applications in drug development in an effort to accelerate the arrival of new therapies.

This is a short summary published by AI Global Wire. The full article is owned and hosted by DIGITIMES — open it there to read it in full.

• OpenAI
• Verktyg
• Forskning